Form D · Pharmaceuticals
PLASMATECH BIOPHARMACEUTICALS INC
Dallas, TX · CIK 0000318306
Offering snapshot reported Jun 1, 2015 · SEC filing
- Reported sold
- $13.7M Offering amount: $22.7M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 15, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 1, 2015 | Initial | $13,664,509 | No comparison | 17 | SEC filing |
| May 22, 2015 | Initial | $10,000,000 | No comparison | 2 | SEC filing |
| Nov 2, 2012 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Nov 14, 2011 | Initial | $5,581,502 | No comparison | 14 | SEC filing |
| Dec 21, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 6, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 1, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-240904
Securities valued at $9,000,000 may be issued upon the realization of certain milestones.
Source: Form D, filed Jun 1, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark J. Ahn | Director |
| Mark J. Ahn, Ph.D. | Director |
| Mark J. Alvino | Director |
| Esteban Cvitkovic, M.D. | Director |
| Jeffrey H. Davis | Director |
| Stephen B. Howell | Director |
| Stephen B. Howell, M.D. | Director |
| Tim Miller | Director, Executive |
| Steven H. Rouhandeh | Executive |
| Stephen B. Thompson | Executive |
| Todd Widder | Director |
| Todd Wider | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4848 Lemmon Avenue Suite 517
Dallas, TX, 75219
Dallas, TX, 75219